Factbox-Pharma sector doubles down on AI amid hopes of slashing costs, timelines | WKZO | Everything Kalamazoo
Publish Date: 2026-01-15 14:18:00
Source Domain: wkzo.com
- Pharmaceutical companies are increasingly leveraging artificial intelligence to enhance R&D processes, aiming to achieve significant efficiencies and reductions in early-stage development timelines and costs.
- Key industry forecasts predict that the application of machine-learning technologies in areas like target discovery, molecule design, and trial planning could halve the time and expense required for early-stage development within the next three to five years.
- Many significant AI-related partnerships were announced between January 2025 and January 2026, involving companies such as Pfizer, Novartis, Lilly, and Merck collaborating with AI firms like NVIDIA, Incyte, and more.
- These partnerships aim to integrate custom AI models, automated lab systems, and large-scale data platforms to accelerate drug discovery and development processes.
